Key Takeaways
- Analysts estimation adjusted EPS of $1.03 vs. $0.58 successful Q3 FY 2020.
- Pfizer gross is expected to turn astatine the fastest gait successful astatine slightest 15 quarters, much than doubling from Q3 FY 2020.
- Pfizer's caller U.S. support for exigency usage of its COVID-19 vaccine successful children ages 5 done 11 is apt to substance further income growth.
Pfizer Inc. (PFE) has experienced melodramatic nett and gross maturation successful caller quarters mostly driven by income of its vaccine against COVID-19 co-developed with German-based BioNTech SE (BNTX). The company's income are apt to support rising astatine a robust gait amid the pandemic, particularly since the U.S. Food and Drug Administration (FDA) connected Oct. 29 authorized the Pfizer-BioNTech vaccine for exigency usage by millions of children 5 done 11 years of age.
Investors volition beryllium watching to spot however accelerated Pfizer's nett and gross maturation volition accelerate erstwhile the institution reports net connected Nov. 2, 2021 for Q3 FY 2021. Analysts expect adjusted net per stock (EPS) and gross to to emergence astatine their fastest gait successful astatine slightest the past 15 quarters.
Pfizer, successful collaboration with BioNTech, was the archetypal institution to person exigency usage authorization (EUA) from the FDA for its vaccine. It received the EUA successful December 2020. On Aug. 23, 2021, Pfizer besides became the archetypal institution to summation afloat support from the FDA for usage of its vaccine successful individuals 16 years of property and older. The institution said its COVID-19 vaccine would present beryllium marketed nether the sanction Comirnaty.
Shares of Pfizer person underperformed the broader marketplace implicit the past year. The banal has outperformed astatine assorted periods passim the past year, but has lagged the marketplace the bulk of the time. Pfizer's shares person provided a full instrumentality of 36.1% implicit the past year, beneath the S&P 500's full instrumentality of 39.1%.
Pfizer Earnings History
Pfizer reported Q2 FY 2021 earnings and gross that surpassed analysts' expectations. Adjusted EPS roseate 72.8% compared to the year-ago quarter. Revenue expanded 92.4% twelvemonth implicit twelvemonth (YOY). It was the fastest gait of maturation for either metric retired of immoderate 4th successful astatine slightest the past 3 and a fractional years. Pfizer's exceptional maturation during the play was driven by income of its vaccine against COVID-19 that it co-developed with BioNTech. The institution raised its guidance for full-year FY 2021.
In Q1 FY 2021, Pfizer's net and gross bushed statement estimates. Adjusted EPS accrued 47.1% compared to the year-ago quarter, marking a important acceleration from the erstwhile quarter's gait of growth. Revenue expanded 44.6% YOY. It was the 2nd consecutive 4th of gross maturation aft six consecutive quarters of declines. Revenue maturation was boosted by income of its COVID-19 vaccine. But adjacent excluding those sales, Pfizer said its operational revenues (revenue that excludes the interaction of overseas speech rates) grew 8%, successful enactment with its extremity of delivering 6% compound yearly maturation done 2025.
Analysts are expecting Pfizer's net and gross maturation to proceed accelerating successful Q3 FY 2021. Adjusted EPS is forecast to emergence 79.3% compared to the year-ago 4th connected gross maturation of 114.7%. For full-year FY 2021, analysts expect adjusted EPS to summation 84.0%. Annual gross is forecast to emergence 92.6%. It would beryllium the fastest gait of maturation for either metric successful astatine slightest the past 4 years.
| Estimate for Q3 FY 2021 | Q3 FY 2020 | Q3 FY 2019 | |
| Adjusted Earnings Per Share ($) | 1.03 | 0.58 | 0.75 |
| Revenue ($B) | 21.9 | 10.2 | 12.7 |
Source: Visible Alpha
Sales of the COVID-19 vaccine are apt to beryllium the main operator of Pfizer's gross implicit the adjacent year. On Sept. 22, 2021, the FDA amended the EUA for the vaccine, approving it for usage arsenic a azygous booster dose administered astatine slightest six months aft completion of the archetypal doses for the pursuing individuals: those 65 years of property and older; those 18 done 64 years of property astatine precocious hazard of terrible COVID-19; and those 18 done 64 years of property who are often exposed to COVID-19 to the grade that it puts them astatine hazard of suffering superior complications.
Investopedia requires writers to usage superior sources to enactment their work. These see achromatic papers, authorities data, archetypal reporting, and interviews with manufacture experts. We besides notation archetypal probe from different reputable publishers wherever appropriate. You tin larn much astir the standards we travel successful producing accurate, unbiased contented successful our editorial policy.
Food and Drug Administration. "FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use successful Children 5 done 11 Years of Age." Accessed Oct. 31, 2021.
Pfizer Inc. "Pfizer Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call with Analysts," Page 1. Accessed Oct. 30, 2021.
Visible Alpha. "Financial Data." Accessed Oct. 29, 2021.
Food and Drug Administration. "FDA Takes Key Action successful Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine." Accessed Oct. 31, 2021.
Food and Drug Administration. "FDA Approves First COVID-19 Vaccine." Accessed Oct. 31, 2021.
Pfizer Inc. "PFIZER REPORTS SECOND-QUARTER 2021 RESULTS," Page 1. Accessed Oct. 31, 2021.
Pfizer Inc. "Form 10-Q for the quarterly play ended April 4, 2021," Page 34. Accessed Nov. 1, 2021.
Pfizer Inc. "PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS," Page 1. Accessed Oct. 31, 2021.
Food and Drug Administration. "FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations." Accessed Oct. 31, 2021.
English (US) ·